The power of standard molecular cloning to accurately profile IRF5 expression in SLE patients and healthy donors is limited by the number of IRF5-positive clones analyzed; a large number of clones would be required to attain a statistically rigorous profile, requiring great resources and financial expenditure. This evidence concerns the gene IRF5 and systemic lupus erythematosus.